Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $99.08 USD
Change Today +0.60 / 0.61%
Volume 72.5K
CBPO On Other Exchanges
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

china biologic products inc (CBPO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/16/15 - $102.80
52 Week Low
05/8/14 - $33.49
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

china biologic products inc (CBPO) Related Businessweek News

No Related Businessweek News Found

china biologic products inc (CBPO) Details

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection for the treatment of original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; human coagulation factor VIII for treating coagulopathie; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; and human cytomegalovirus immunoglobulin. It distributes its products directly or through distributors. The company is headquartered in Beijing, the People's Republic of China.

1,621 Employees
Last Reported Date: 03/4/15

china biologic products inc (CBPO) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $885.4K
Chief Financial Officer
Total Annual Compensation: $366.5K
Senior Corporate Vice President and Corporate...
Total Annual Compensation: $256.8K
Corporate Vice President and General Manager ...
Total Annual Compensation: $324.5K
Corporate Vice President
Total Annual Compensation: $183.6K
Compensation as of Fiscal Year 2014.

china biologic products inc (CBPO) Key Developments

China Biologic Products, Inc. to Report Q1, 2015 Results on May 06, 2015

China Biologic Products, Inc. announced that they will report Q1, 2015 results at 5:00 PM, China Standard Time on May 06, 2015

China Biologic Products Seeks Acquisitions

China Biologic Products, Inc. (NasdaqGS:CBPO) is seeking acquisitions. Ming Yang, Chief Financial Officer of China Biologic, said "If a right opportunity arises, the funding, the acquisition, it never will be a problem for us because we have a large untapped loan facility if we need it."

China Biologic Products, Inc. Announces Board Changes

China Biologic Products, Inc. announced that on March 2, 2015, Mr. Dai Feng resigned from the board of directors of the Company, effective from the same date. On the same date, the Board appointed Mr. Min Fang, as a director of the Company with immediate effect to fill the vacancy resulting from Mr. Fang's resignation from the Board. Mr. Fang has been a principal at Beijing Warburg Pincus Investment Consulting Company Limited Shanghai Branch since July 2011, and a core member of the China healthcare team. In addition to his role with the Company, Mr. Fang currently serves on the board of several private companies including, among others, EA Inc. and Beijing Amcare Women's and Children's Hospital Co. Ltd.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBPO:US $99.08 USD +0.60

CBPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hualan Biological Engineering Inc CNY53.89 CNY -1.99
Jiangxi Boya Bio-Pharmaceutical Co Ltd CNY75.46 CNY 0.00
Shanghai RAAS Blood Products Co Ltd CNY60.80 CNY -0.88
View Industry Companies

Industry Analysis


Industry Average

Valuation CBPO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA BIOLOGIC PRODUCTS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at